Clinical pharmacology of polyestradiol phosphate

@article{Gunnarsson1988ClinicalPO,
  title={Clinical pharmacology of polyestradiol phosphate},
  author={Per Olov Gunnarsson and Bo Johan Norl{\'e}n},
  journal={The Prostate},
  year={1988},
  volume={13}
}
The results of the present studies demonstrate that intramuscular injections of polyestradiol phosphate (PEP) produce not only considerably increased estrogen concentration in plasma but also maintain the same estrone/estradiol ratio as in normal men. 
Pharmacokinetics and testosterone suppression of a single dose of polyestradiol phosphate (Estradurin®) in prostatic cancer patients
The pharmacokinetics and endocrine effects of polyestradiol phosphate (PEP; Estradurin®) were studied by determination of the concentrations of estradiol (E2), unconjugated (E1) and total estroneExpand
Steroid phosphate esters and phosphonosteroids and their biological activities
TLDR
Phosphonosteroids demonstrate antineoplastic and antihypercholesterolemic activities with a certainty of 85 to 90%. Expand
Vastly extended drug release from poly(pro-17β-estradiol) materials facilitates in vitro neurotrophism and neuroprotection
TLDR
First-generation poly(pro-E2) biomaterial scaffolds that release E2 at nanomolar concentrations over the course of 1–10 years via slow hydrolysis in vitro demonstrate the first step towards next-generation implantable biomaterials with prolonged release and excellent regenerative potential. Expand
Differential reaction of secretory and non‐secretory proteins in hormone‐treated dunning tumor
TLDR
The findings indicate that different hormonal situations provide conditions for the development of rather heterogeneous reaction patterns of different tumor cells, allowing partial regression of individual clones of tumor cells along with stimulation of others. Expand
In Silico Prediction of Steroids and Triterpenoids as Potential Regulators of Lipid Metabolism
TLDR
This review focuses on a rare group of steroids and triterpenoids that share common properties as regulators of lipid metabolism and related processes such as anti-hyperlipoproteinemic activity, as well as the treatment of atherosclerosis, lipoprotein disorders, or inhibitors of cholesterol synthesis. Expand

References

SHOWING 1-7 OF 7 REFERENCES
Treatment of prostatic carcinoma with various types of estrogen derivatives.
TLDR
It appears that EMP may be valuable in advanced cases that are unresponsive to other estrogen therapies, and exhibited stronger estrogenic effects than PEP alone. Expand
Plasma concentrations of estradiol and testosterone in single-drug polyestradiol phosphate therapy for prostatic cancer.
To evaluate the appropriate dosage of polyestradiol phosphate (PEP, Estradurin) as single-drug therapy, patients with metastatic prostatic carcinoma were given 80, 160 or 240 mg PEP every 4 weeks forExpand
Cardiovascular follow‐up of patients with prostatic cancer treated with single‐drug polyestradiol phosphate
TLDR
Patients with cancer of the prostate treated with strict parenteral estrogen in the form of monthly polyestradiol phosphate injections have responded to therapy and there have been no cardiovascular complications at a mean follow‐up of 12.9 ± 0.7 months. Expand
Optimal testosterone concentration for the treatment of prostatic cancer.
TLDR
A threshold of serum testosterone exists below which the Dunning R3327H tumor is inhibited from growing but is compatible with relatively normal sexual activity, and therapy might be individualized to minimize side effects such as the loss of sexual activity. Expand
A comparison of androgen status in patients with prostatic cancer treated with oral and/or parenteral estrogens or by orchidectomy
TLDR
Both estrogen treatment regimens were as effective as orchidectomy in reducing circulating levels of T and A‐4 and the more pronounced effects of oral estrogens on circulating adrenal androgens may reflect an altered liver metabolism associated with this route of administration. Expand
Effectiveness of complete versus partial androgen withdrawal therapy for the treatment of prostatic cancer as studied in the Dunning R-3327 system of rat prostatic adenocarcinomas.
TLDR
It is demonstrated that complete androgen withdrawal consisting of surgical castration in combination with daily treatment with the potent antiandrogen, cyproterone acetate, was no more effective in terms of tumor growth retardation or overall host survival than was partial androgens withdrawal induced by castration alone. Expand